title: Aberrant expression of Per1, Per2 and Per3 and their prognostic relevance in non-small cell lung cancer.
abstract: The objective of the current study was to investigate the expression pattern and clinicopathological significance of Period1 (Per1), Period2 (Per2) and Period3 (Per3) in patients with non-small cell lung cancer (NSCLC). In 130 archived NSCLC tissues, the positive rate of Per1 (86/130, 66.2%), Per2 (77/130, 59.2%) and Per3 (82/130, 63.1%) were reduced in human lung cancer samples compared with adjacent normal lung tissues (Per1, 119/130, 91.5%; Per2, 115/130, 88.5%; Per3, 121/130, 93.1%), as measured by immunohistochemical staining. Loss of Per1 was correlated with poor differentiation (P < 0.001), tumor status (P=0.04), high p-TNM stage (P < 0.001) and lymph node metastasis (P=0.045). The similar tendencies were also found in the correlation of the expression of Per2 and Per3 with clinicopathological factors. In addition, a significant correlation was found between Per1 and Per2 (P < 0.001) in 130 cases of NSCLC. Similarly, a significant correlation was found between Per2 and Per3 (P=0.045). Patients with lower expression of Per1, Per2 and Per3 had a shorter survival time than those with higher expression. These results indicate that loss of Per may promote tumor progression in NSCLC, and may serve as a novel prognostic biomarker of NSCLC.
authors.affiliation: Department of Medical Oncology, Liaoning Cancer Hospital and Institute Shenyang 110042, Liaoning, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.affiliation: Department of Thoracic Surgery, Liaoning Cancer Hospital and Institute Shenyang 110042, Liaoning, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Xu
authors.affiliation: Class 2 of The 97th Clinical Medicine of Seven-Year Program, China Medical University Shenyang 110001, Liaoning, China.
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Medical Oncology, Liaoning Cancer Hospital and Institute Shenyang 110042, Liaoning, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D056950:Period Circadian Proteins / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C539022:PER1 protein, human; C421902:PER2 protein, human; C512644:PER3 protein, human; D056950:Period Circadian Proteins
keywords: Period1; Period2; Period3; immunohistochemistry; non-small cell lung cancer; prognosis